SYRS vs. TRVN, ARDS, EVLO, GNCAQ, GNCA, STAB, AMPE, CMRA, CLVR, and EFTR
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry.
Syros Pharmaceuticals vs. Its Competitors
Syros Pharmaceuticals (NASDAQ:SYRS) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.
In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.
Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.
Trevena has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.
Syros Pharmaceuticals presently has a consensus price target of $1.00, suggesting a potential upside of 19,900.00%. Trevena has a consensus price target of $5.00, suggesting a potential upside of 41,566.67%. Given Trevena's higher probable upside, analysts clearly believe Trevena is more favorable than Syros Pharmaceuticals.
91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
Summary
Syros Pharmaceuticals beats Trevena on 6 of the 11 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SYRS) was last updated on 10/9/2025 by MarketBeat.com Staff
